Biotron Valuation

Is BIT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BIT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BIT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIT?

Key metric: As BIT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BIT. This is calculated by dividing BIT's market cap by their current revenue.
What is BIT's PS Ratio?
PS Ratio	10.4x
Sales	AU$1.65m
Market Cap	AU$17.14m

BIT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	10.2x
Enterprise Value/EBITDA	-4.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BIT's PS Ratio compare to its peers?

The above table shows the PS ratio for BIT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.5x
ATH Alterity Therapeutics	4x	25.0%	AU$16.0m
1AD AdAlta	6.6x	n/a	AU$11.5m
ATX Amplia Therapeutics	5.6x	n/a	AU$24.7m
MDC Medlab Clinical	9.8x	41.7%	AU$15.1m
BIT Biotron	10.4x	n/a	AU$17.1m

Price-To-Sales vs Peers: BIT is expensive based on its Price-To-Sales Ratio (10.4x) compared to the peer average (5.4x).

Price to Sales Ratio vs Industry

How does BIT's PS Ratio compare vs other companies in the AU Biotechs Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
ARX Aroa Biosurgery	3.6x	20.1%	US$146.13m
IMC Immuron	3.5x	59.7%	US$11.20m
ATH Alterity Therapeutics	4x	25.0%	US$10.40m
BNO Bionomics	2.4x	-5.3%	US$9.52m

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BIT is expensive based on its Price-To-Sales Ratio (10.4x) compared to the Australian Biotechs industry average (10x).

Price to Sales Ratio vs Fair Ratio

What is BIT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	10.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BIT's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.13

6.1%

AVITA Medical

US$339.9m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.92

2.3%

25.0%

AVITA Medical

US$342.3m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.97

0.3%

19.6%